SecBot SecBot
144 ·Filed Nov 4, 2026

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed12d 6h ago SEC0001973379-26-000356
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine option exercise and sale by a senior executive, not a material insider signal. Monitor for any pattern of larger insider sales in future Form 4 filings, but this single filing is not actionable.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$41.78
T+0 close · Nov 4, 2026 · via day close
Latest settled
+4.48%
T+5 · $43.65 · next T+20 in 17d
Vs SPY
+1.19%
α at T+5
Latest observation
+6.70%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $41.78entry
  2. T+1 · 11d ago +1.99%α +1.67% · $42.61
  3. T+5 · 5d ago +4.48%α +1.19% · $43.65
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dov Bergwerk, Teva's Senior VP, General Counsel and Corporate Secretary, filed a Form 144 notice to sell 26,260 ordinary shares with an approximate market value of $1.1 million. The sale is tied to a stock option exercise and sale transaction, executed on the filing date at an indicative price of $41.72 per share. Relative to Teva's $47.4B market cap, the sale is small and routine for an executive exercising options.

Key Facts

  • Insider: Dov Bergwerk, Senior VP General Counsel Corporate Secretary
  • Shares to be sold: 26,260 ordinary shares
  • Approximate value: $1,095,567.20
  • Indicative price: $41.72 per share
  • Transaction type: stock option exercise and sale
  • Filing date: November 4, 2026
  • Broker: Citigroup Global Markets, Inc.

Financial Impact

Approximately $1.1 million sale, representing about 0.002% of Teva's $47.4B market cap

dilution

Risk Factors

  • Form 144 is an intent to sell; the actual sale may not occur
  • No context on the insider's remaining holdings, so the proportional impact on his personal position is unknown

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001973379-26-000356
Document: 0001973379-26-000356-index.html0001973379-26-000356
Document: 0001973379-26-000356.txt0001973379-26-000356

Track record

61 reports on TEVA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
  2. Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
  6. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  7. Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  9. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  10. Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
Showing 10 of 61

US Market Status

Market Closed · Opens Wed (10h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026